泽璟制药：2025年净亏损1.61亿元

Core Viewpoint - ZaiJing Pharmaceutical reported a revenue of 813 million yuan for the year 2025, marking a year-on-year increase of 52.50%, while the net loss attributable to shareholders was 161 million yuan, compared to a net loss of 138 million yuan in the same period last year [1] Financial Performance - The total assets of the company at the end of 2025 amounted to 2.971 billion yuan, with equity attributable to the parent company reaching 1.083 billion yuan [1] Product Development and Market Expansion - The company successfully launched Jikaxitini tablets, aiming to expand market coverage [1] - The recombinant human thrombin was officially included in the national medical insurance directory, leading to a rapid increase in the number of hospitals and sales through collaboration with exclusive marketing partners [1] - The company continued to advance new drug research and development, resulting in an increase in R&D expenses year-on-year due to varying stages of development for different projects [1]